Education
About Us
Working with TipRanks
Follow Us
Mckesson Corp. (MCK)
NYSE:MCK
MCK Stock Chart & Stats
$962.32
$1.72(0.29%)
At close: 4:00 PM EST
$962.32
$1.72(0.29%)
Day’s Range― - ―
52-Week Range$583.55 - $971.93
Previous CloseN/A
Volume137.88K
Average Volume (3M)646.68K
Market Cap
$116.20B
Enterprise Value$124.45B
Total Cash (Recent Filing)$2.96B
Total Debt (Recent Filing)$8.62B
Price to Earnings (P/E)27.3
Beta0.27
Next Earnings
May 13, 2026EPS Estimate
11.55Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)9.34
Shares Outstanding122,487,460
10 Day Avg. Volume960,603
30 Day Avg. Volume646,685
Financial Highlights & Ratios
PEG Ratio1.77
Price to Book (P/B)-41.34
Price to Sales (P/S)0.24
P/FCF Ratio16.41
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue0.31
Enterprise Value/Gross Profit9.27
Enterprise Value/Ebitda19.24
Forecast
1Y Price Target
$974.09Price Target Upside1.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Earnings And GuidanceAnalyst's recommendation is supported by McKesson beating revenue and earnings expectations and raising full-year adjusted earnings and operating income guidance, signaling stronger operating results.
Private-label Biosimilars StrategyAddition of a pegfilgrastim biosimilar to Northstar Rx and a partnership with an experienced contract manufacturer positions the company to scale higher-margin private-label biosimilars and leverage its oncology provider network to drive uptake.
Specialty And Oncology GrowthManagement expects stable utilization and continued specialty distribution growth, and the oncology and multispecialty segment is outperforming forecasts, supporting expansion in higher-margin areas.
Bears Say
GLP-1 Pricing PressureDeclining prices for GLP-1 drugs could reduce demand for prior authorization and prescription technology services, pressuring revenue in that business line.
High Market ExpectationsElevated investor expectations may limit upside and lead to muted stock reactions if performance only modestly exceeds forecasts.
Medical-surgical Segment WeaknessLower physician office volumes and a milder illness season have weakened medical-surgical results, creating a headwind for overall segment profitability.
McKesson News
MCK FAQ
What was Mckesson Corp.’s price range in the past 12 months?
Mckesson Corp. lowest stock price was $583.55 and its highest was $971.93 in the past 12 months.
What is Mckesson Corp.’s market cap?
Mckesson Corp.’s market cap is $116.20B.
When is Mckesson Corp.’s upcoming earnings report date?
Mckesson Corp.’s upcoming earnings report date is May 13, 2026 which is in 92 days.
How were Mckesson Corp.’s earnings last quarter?
Mckesson Corp. released its earnings results on Feb 04, 2026. The company reported $9.34 earnings per share for the quarter, beating the consensus estimate of $9.173 by $0.167.
Is Mckesson Corp. overvalued?
According to Wall Street analysts Mckesson Corp.’s price is currently Undervalued.
Does Mckesson Corp. pay dividends?
Mckesson Corp. pays a Quarterly dividend of $0.82 which represents an annual dividend yield of 0.37%. See more information on Mckesson Corp. dividends here
What is Mckesson Corp.’s EPS estimate?
Mckesson Corp.’s EPS estimate is 11.55.
How many shares outstanding does Mckesson Corp. have?
Mckesson Corp. has 122,487,460 shares outstanding.
What happened to Mckesson Corp.’s price movement after its last earnings report?
Mckesson Corp. reported an EPS of $9.34 in its last earnings report, beating expectations of $9.173. Following the earnings report the stock price went up 16.521%.
Which hedge fund is a major shareholder of Mckesson Corp.?
Currently, no hedge funds are holding shares in MCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
McKesson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$974.09 (1.22% Upside)
$974.09 (1.22% Upside)
Blogger Sentiment
Bullish
MCK Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 9.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bullish
Bullish news 97%
Bearish news 3%
Bearish news 3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
18.44%
Trailing 12-Months
Company Description
Mckesson Corp.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
MCK Company Deck
MCK Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and financial picture: strong double-digit top-line and EPS growth, raised full-year guidance, robust segment performance (notably oncology, specialty distribution and RxTS), solid cash generation, active buybacks, and successful acquisition integrations. Challenges are relatively contained: medical-surgical profitability pressure, quarter-to-quarter variability driven by seasonality/launch timing, and some uncertainty around GLP-1 channel evolution and near-term technology investment costs. Overall, the positives (growth, margin expansion, cash flow, strategic progress) materially outweigh the noted headwinds.View all MCK earnings summariesMCK Revenue Breakdown
91.27% U.S. Pharmaceutical
1.45% Prescription Technology Solutions
3.17% Medical-Surgical Solutions
4.10% International
<0.01% Corporate
MCK Stock 12 Month Forecast
Average Price Target
$974.09
▲(1.22% Upside)
Technical Analysis
Ownership Overview
0.03% Insiders
23.73% Mutual Funds
0.36% Other Institutional Investors
54.00% Public Companies and Individual Investors